| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Our goal is to establish an effective treatment for gastric cancer. By using newly established mouse and human gastric cancer organoids, we tried to identify cancer-initiating cells and clarify the mechanism which induce their malignancy. Furthermore, based on knowledges, we searched for an effective treatment for gastric cancer in vivo. We proceeded our research with focusing on an epithelial stem cell marker, LGR5 and found that LGR5 positive gastric cancer cells could be the cancer-initiating cell. By a comprehensive gene expression analysis, we found a group of genes which could regulate proliferation and maintenance of cancer-initiating cells. We orthotopically transplanted genetically modified organoids into mouse stomach and found that some genes can regulate the metastatic ability of cancer-initiating cells. Furthermore, we found drug candidates which can selectively eliminate cancer-initiating cells.
|
